Curis (NASDAQ:CRIS) Issues Quarterly Earnings Results, Beats Estimates By $1.66 EPS

Curis (NASDAQ:CRIS) announced its quarterly earnings data on Thursday. The biotechnology company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $1.66, FiscalAI reports. The firm had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $3.25 million.

Here are the key takeaways from Curis’ conference call:

• Take Aim Lymphoma (PCNSL) registrational study is enrolling on track and, after FDA/EMA discussions, is expected to support accelerated submissions, with full enrollment targeted in ~12–18 months and a potential filing timeline into 2027.
• Curis has initiated a proof-of-concept CLL trial adding emavusertib to BTKI to deepen responses and enable time-limited therapy; U.S. and EU sites are activating and the company expects initial data at ASH (Dec 2026).
• Early data from the AML triplet study (emavusertib + azacitidine + venetoclax) showed promising activity, with 5 of 8 evaluable patients converting from MRD positive to undetectable disease, though the cohort size is small.
• Q4 2025 net income of $19.4M was driven by a $27.2M one-time non-cash gain from the sale of Erivedge, and management expects no meaningful revenue going forward after that sale.
• Company reports cash and equivalents plus January 2026 proceeds should fund operations into the second half of 2027, with up to an additional $20.2M contingent on exercise of warrants triggered by dosing the fifth CLL patient.

Curis Stock Performance

Curis stock traded down $0.06 during trading on Thursday, reaching $0.76. 395,278 shares of the company’s stock were exchanged, compared to its average volume of 561,066. Curis has a 52-week low of $0.75 and a 52-week high of $3.13. The company’s 50-day moving average is $0.98 and its two-hundred day moving average is $1.26. The firm has a market cap of $10.40 million, a price-to-earnings ratio of -0.21 and a beta of 3.02.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Curis currently has an average rating of “Hold” and a consensus price target of $17.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CRIS. Armistice Capital LLC boosted its position in Curis by 8.7% in the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares during the last quarter. Maverick Capital Ltd. grew its position in shares of Curis by 7.8% in the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after acquiring an additional 49,554 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Curis by 2,883,237.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 230,659 shares during the period. Finally, Squarepoint Ops LLC boosted its stake in Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 27,343 shares during the period. 29.97% of the stock is currently owned by hedge funds and other institutional investors.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.